Accelerate Diagnostics Revenue Charts (NASDAQ:AXDX)
$27.6 $0.05 (0.18%) AXDX stock closing price Jul 21, 2017 (Closing)
The latest 2017-Q1 Accelerate Diagnostics revenue is 0.5M. Compare Accelerate Diagnostics revenue chart with ArthroCare revenue, Cynosure revenue.
Accelerate Diagnostics Revenue Chart
You can do annual as well as quarterly comparisons of Accelerate Diagnostics Inc net sales with its competitor companies like ArthroCare, Cynosure. Over the 5 year period Accelerate Diagnostics revenue in 2016 was highest at 0.24M. In the latest quarter, AXDX revenue 2017-Q1 has changed from 0.04M to 0.5M implying an increase of 1150%.
Accelerate Diagnostics Quarterly Revenue
* Past 5 years Range
|Max AXDX Revenue||$0.5M||Mar, 2017|
|Min AXDX Revenue||$0.01M||Mar, 2012|
Accelerate Diagnostics Annual Revenue
* Past 5 years Range
|Max AXDX Revenue||$1.12M||Dec, 2011|
|Min AXDX Revenue||$0.04M||Dec, 2013|
Accelerate Diagnostics Annual Revenue VS Peers
|Accelerate Diagnostics Revenue||$0.24M||$0.14M||$0.12M||$0.04M||$1.12M|
|Wafergen Biosystems Revenue||----||$7.16M||$6M||$1.3M||$0.58M|
|Bruker Corp Revenue||$1.61B||$1.62B||$1.81B||$1.84B||$1.79B|
|Thermo Fisher Scientific Revenue||$18.27B||$16.97B||$16.89B||$13.09B||$12.51B|
Accelerate Diagnostics Stock Articles
Accelerate Diagnostics News
Revenue or net sales is the total amount of money that a company brings in through its various business activities. Revenue is also known as the top line or net sales or gross income. Revenue is for a specific period of time and appears as the "top line" in an income statement. By subtracting the costs or expenses from Accelerate Diagnostics topline we arrive at the bottom line for the company. Increasing revenues over a period of time is generally a sign of a healthy company, however other factors need to be taken into consideration. Revenue can be calculated in two ways based on the type of accounting followed: accrual accounting or cashflow accounting. It helps to compare Accelerate Diagnostics revenue with peers ArthroCare topline, Cynosure topline, Wafergen Biosystems topline; to see how the company is doing with respect to its peers.